| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 12, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 300 | $3.75 | 2,300 | |
| June 16, 2008 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 400 | $4.38 | 27,067 | |
| June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 400 | $4.38 | 27,067 | |
| November 19, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 404 | $2.50 | 8,404 | |
| December 5, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 490 | $2.10 | 47,397 | |
| December 20, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 500 | $1.77 | 80,500 | |
| May 17, 2007 | President, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 600 | $4.82 | 10,000 | |
| April 13, 2010 | Interim Chief Accounting Off. | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 700 | -- | 7,700 | |
| April 13, 2010 | Interim Chief Accounting Off. | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 700 | -- | 21,400 | |
| March 20, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 800 | $4.20 | 1,800 | |
| March 14, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4/A | Open market or private purchase of non-derivative or derivative security | 800 | $4.05 | 1,000 | |
| March 14, 2006 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 800 | $4.05 | 1,000 | |
| September 10, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,060 | $4.92 | 69,487 | |
| September 10, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,549 | $4.97 | 74,936 | |
| September 22, 2010 | Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,550 | $3.03 | 28,087 | |
| October 29, 2007 | Chief Accounting Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,666 | $6.10 | 15,000 | |
| October 29, 2007 | Chief Accounting Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,666 | $6.10 | 15,000 | |
| October 29, 2007 | Chief Accounting Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,666 | $6.10 | 15,000 | |
| May 12, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,700 | $3.75 | 4,000 | |
| May 26, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,727 | $2.77 | 12,800 | |
| May 26, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,727 | $0.12 | 5,060 | |
| June 13, 2022 | Chief Accounting Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,750 | -- | 5,833 | |
| May 17, 2007 | President, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,784 | $4.81 | 9,400 | |
| June 16, 2008 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,800 | $4.40 | 29,167 | |
| June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 1,800 | $4.40 | 29,167 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
